Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently the most important emerging pathogen worldwide, but its early transcriptional dynamics and host immune response remain unclear. Herein, the expression profiles of viral interactions with different types of hosts were comprehensively dissected to shed light on the early infection strategy of SARS-CoV-2 and the host immune response against infection. SARS-CoV-2 was found to exhibit a two-stage transcriptional strategy within the first 24 h of infection, comprising a lag phase that ends with the virus being paused and a log phase that starts when the viral load increases rapidly. Interestingly, the host innate immune response was found not to be activated (latent period) until the virus entered the log stage. Noteworthy, when intracellular immunity is suppressed, SARS-CoV-2 shows a correlation with dysregulation of metal ion homeostasis. Herein, the inhibitory activity of copper ions against SARS-CoV-2 was further validated in in vitro experiments. Coronavirus disease 2019-related genes (including CD38, PTX3, and TCN1) were also identified, which may serve as candidate host-restricted factors for interventional therapy. Collectively, these results confirm that the two-stage strategy of SARS-CoV-2 effectively aids its survival in early infection by regulating the host intracellular immunity, highlighting the key role of interferon in viral infection and potential therapeutic candidates for further investigations on antiviral strategies.
Introduction: The Early Infection "Black Box"
While the global medical community has extensively studied the late-stage "cytokine storm" associated with severe COVID-19, the events occurring within the first 24 hours of infection have remained a biological "black box." Understanding how SARS-CoV-2 establishes a foothold before the host’s innate immune system can react is critical for developing early intervention strategies. This study maps the early transcriptional dynamics of the virus and investigates why the host's initial immune response often fails to contain the threat.
Methodology
The researchers employed a multi-pronged approach combining high-resolution sequencing with advanced bioinformatics:
- Time-Course RNA-Seq: Host and viral RNA were sequenced every two hours for the first 24 hours post-infection.
- Comparative Cell Models: Three cell lines were used to isolate the role of Type I Interferon (IFN): Vero E6 (IFN-deficient), Huh7 (IFN-normal), and Huh7.5.1 (IFN-deficient).
- Network Analysis & Machine Learning: Weighted Gene Co-expression Network Analysis (WGCNA) identified hijacked cellular processes, while a Random Forest algorithm analyzed clinical data from 100 COVID-19 patients (GSE157103) to identify key biomarkers.
- In Vitro Validation: The inhibitory effects of copper sulfate ($CuSO_4$) on viral replication were tested using qRT-PCR and immunofluorescence.
Results: A Two-Stage Takeover
Viral Transcriptional Dynamics
The study revealed that SARS-CoV-2 does not begin rapid replication immediately upon entry. Instead, it employs a tactical lag phase (approximately the first 10–14 hours) where viral activity is effectively "paused." This delay appears to prevent the host cell from detecting viral RNA prematurely. Once this period ends, the virus enters a log phase characterized by rapid expansion.
In Vero E6 cells, the mapping rate of SARS-CoV-2 jumped from negligible levels to over 26% by 22–24 hours post-infection. Crucially, the host's innate immune response remained latent during the lag phase; the "interferon alarm" only triggered once the virus entered the log stage, by which point the viral load was already substantial.
Growth Rate and Immune Latency
Quantitative analysis of growth rates for both structural and non-structural genes confirmed this distinct shift. In cells with normal IFN responses (Huh7), viral accumulation was significantly lower than in IFN-deficient cells (Huh7.5.1), confirming that early IFN signaling is the primary barrier the virus must circumvent.
Key Insights: Copper and Biomarkers
The Copper Battlefield
When host intracellular immunity is suppressed, the virus correlates strongly with the dysregulation of metal ion homeostasis. In vitro experiments demonstrated that copper ions ($CuSO_4$) effectively inhibit SARS-CoV-2 replication in a dose-dependent manner, particularly in Vero E6 cells. This suggests the virus may actively interfere with copper levels to facilitate its survival.
Clinical Biomarker Trio
Through machine learning analysis of clinical transcriptomes, the researchers identified CD38, PTX3, and TCN1 as critical "host-restricted factors." These genes are deeply involved in the inflammatory response and can accurately distinguish severe COVID-19 cases. Specifically, CD38 achieved an Area Under the Curve (AUC) of 0.91, marking it as a top-tier biomarker for clinical severity.
Conclusion and Future Directions
This research highlights the "lag phase" as a critical window for prophylactic or early therapeutic intervention. By understanding the virus's two-stage strategy and its reliance on suppressing host immunity and metal ion homeostasis, new treatments—such as early IFN-boosting therapies or copper-based interventions—can be explored. Future work will focus on validating these biomarkers in larger clinical cohorts and elucidating the exact molecular mechanisms by which copper inhibits viral machinery.
Summary updated